A recent article in Seattle Business Magazine discussed the growth of Seattle Genetics. It’s no doubt that huge things are on the horizon for this titan company. Co-founder of Seattle Genetics, Dr. Clay Siegall, stated that the goal is for Seattle Genetics to continue to emerge as a global leader the oncology field.
The company specializes in a multitiude of products. In the article, Dr. Siegall states the depth of products that his company has coming down the pipe and relates it to the future of Seattle Genetics. As a company continues to rise as this one has, it often makes it an attractive candidate for acquisition. Dr. Siegall points to the mass of products in the pipeline as one of the reasons he wants to continue to grow his company and make it a truly great one, rather than simply sell to a larger existing biotech firm.
One of the biggest things for Seattle Genetics is the development of human antibodies that are capable of releasing a large, and deadly goal of antibodies inside of cancer cells or an individual cell. This process actaully destroys the cancer cell from the inside out.
Seattle Genetics is an up and coming leader in the biotech field and is currently the largest in its vertical in Washington. The company currently has a market value of around $10 billion and employs over 900 people, expecting to add over 200 this year to work thoroughly in research and marketing departments.
Seattle Genetics was founded by Clay B. Siegall, Ph.D., and he is currently the company’s President, CEO, Chairman of the Board of Directors and an outside director to the Board. His overarching vision is to drive his company to greatness and become one of the few that move from the biotech space into the world of big pharmaceuticals. Dr. Siegal has been published over 70 times and has 15 patents. He holds a Ph.D in Genetics from George Washington University and a bachelors degree in Zoology from the University of Maryland.
Siegall has, in recent years, made the wise decision to pivot Seattle Genetics to focus a larger spectrum of time on executing global marketing of its products. Thesse products rolling out globally tend to be newer drugs. This is again help push them toward the forefront of the biotech and research space rather than the most raditional role of a biotech company that would likely be acquired at this space in their growth trajectory.